Non TNFi b/tsDMARDs vs TNFi in RA-ILD. New-User, Propensity Score Matched Study. 454 patients. No difference! resp-related hospitalisation aHR 1.22 [0.92, 1.60] No difference mortality. Abstr#1582 #ACR23 #ACRbest @RheumNow https://t.co/HzzVo9dJHi https://t.co/mZuHq4GShU

The SMART study by Dhir et al: once-weekly, oral split-dose MTX (10mg/15mg) in RA pts had⬆️efficacy & ⬇️need for addtl DMARDs vs. once-weekly, single-dose MTX Reassuring. . . . In my practice, pts tolerate MTX split dosing better esp w/⬆️doses #ACR23 ABST1583 @RheumNow https://t.co/F8p2aKmmH4

#ACR23 Abs #1032 identified six major themes of diverse patient experiences. Studying patient experiences is critical for understanding mechanisms of health disparity, targeting interventions and, ultimately, improving quality of care. https://t.co/Fd2m4yzlHp @rheumnow https://t.co/EhIIF9cquQ

Long term follow up T2T in RA 12 yrs BeST & 20yrs IMPROVED studies 50% recalled 68% remission 91% LDA HAQ 0.5 These are GOOD outcomes Especially considering setup before we had several MoAs What’s lacking: current ttmt & number of bioD, ctrl group @RheumNow ABST1273 #ACR23 https://t.co/9KcsHLupJc

#ACR23 Abstr#1579 More data on the role of SGLT2-i in #SLE. Data from EHR using propensity match scoring showed the use of SGLT2-i vs DPP4-i (for nonSLE indication) was associated with reduced risk of MACE (HR:0.69)and poor renal outcomes inc. ESRD (HR:0.71) @RheumNow https://t.co/7k0o3m18AN

Does NSAID use = CKD? Large Korean study on CKD in ankylosing spondylitis pts showed risk of CKD associated with comorbidities. Long term NSAID use not associated with increased risk of CKD. @RheumNow #ACR23 Abs#1394 https://t.co/m3kYI30gBc

OA and Microbiome! Ab#1581 @RheumNow #ACR23 Microbiome transplantation of mouse models - benefit if before or soon after OA induction (meniscal destabilization) ⭐️OA is inflammatory dis of innate immune sys, not "wear-and-tear" and gut biome may be a 🔑 https://t.co/eA8unUBnpC

Risk of CKD in AS patients was associated with comorbidities, not NSAID use. #ACR23 Abs #1394 https://t.co/cbOPvjOCyq @rheumnow https://t.co/O0rhbMFiOX

Majority of pts with axSpA had below avg aerobic capacity indicating high risk of morbidity. Importance of supporting pts with axSpA to lead healthy lifestyle and improved aerobic capacity by exercise! @RheumNow #ACR23 Abs#1395 https://t.co/SFAStGQaK0

Apremilast associated with improvement in LDL, obesity and diabetic A1c in PsA pts, especially in those with worse levels at baseline! Can consider apremilast use in PsA with high burden of comorbid cardiometabolic diseases @RheumNow #ACR23 Abs#1414 https://t.co/fL9UWcaZgG

RA-ILD is an heterogeneous condition Different risk factors identified dep/ on radiographic pattern RA-UIP: -male sex OR 2.7 -ACPA+ OR 2.2 -male + ACPA + smoking OR 13 RA-NSIP: -RF+ OR 3.2 Likely to support different pathological mechanisms @RheumNow #ACR23 ABST1269 https://t.co/rC2F9YAceQ